Our Impact Statement

Over the last 30 years, survival rates for GI cancers have increased. Community support has been vital to this change – there has been a notable shift in the zeitgeist around awareness and support for cancers with low survival rates.

Gastro-Intestinal (GI) cancer is a term for the group of cancers that affect the digestive system. This includes cancers of the oesophagus, gallbladder & biliary tract, liver, pancreas, stomach, small intestine, bowel (large intestine or colon and rectum), and anus. It also includes rare cancers like neuroendocrine tumours and gastro-intestinal stromal tumours, which can occur throughout the gastro-intestinal system.

GI cancer is the most common form of cancer. Around 28,900 Australians are diagnosed with it each year and 38 Australians die of it each day.

GI cancer survival rates: 1982-7 to 2018

Our Impact

The GI Cancer Institute was formed in 1991 to conduct clinical trials and research to change these outcomes. Our contributions include:

27 years of ground-breaking research, giving patients access to new treatments 3-5 years faster than if the research had been conducted overseIf yas. Over $55 million invested in clinical trials, helping the 28,900 Australians diagnosed each year. 4,000+ patients given access to new treatment regimens. 57 clinical trials run across all GI cancer areas, improving outcomes for people with GI cancer. 92 centres participating in our clinical trials, making new treatments available to patients right across the country. 9 new research priorities ensuring our research continues to have the patient at the centre of everything we do.

More information about GI cancer is available here.

To support our work by making a donation, click here:

Donate Now

Share